# Poolbeg Pharma Immunomodulator II patent granted in Japan

- Link: https://www.directorstalkinterviews.com/poolbeg-pharma-immunomodulator-ii-patent-granted-in-japan/4121133487
- Published: 2023-11-21T07:10:33+00:00
- Author: Emily Johnson

**[Poolbeg Pharma Plc](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l)**(
[LON:POLB](https://www.directorstalkinterviews.com/company/poolbeg-pharma-plc/polb.l),
OTCQB: POLBF), a biopharmaceutical company focussed on the development and commercialisation
of innovative medicines targeting diseases with a high unmet medical need, has announced
that the Japanese Patent Office has notified the Company of its official decision
to grant Poolbeg’s Immunomodulator II patent application.

The claims cover the pharmaceutical composition of POLB 001 for treating severe 
influenza in a hospitalised patient in combination with antiviral compounds, further
strengthening the Company’s robust intellectual property in the territory. The formal
granted patent will be received in due course.

In addition, further to the Company’s announcement on [20 September 2023](https://www.directorstalkinterviews.com/poolbeg-pharma-plc-granted-allowance-from-the-japanese-patent-office/4121127709),
it has received the fully granted patent for Immunomodulator I from the Japanese
Patent Office.

Poolbeg Pharma Plc has a worldwide licence for POLB 001 for all uses in humans and
is developing a strong IP portfolio with patents in place, including Immunomodulator
I and Immunomodulator II, covering the use of the class of p38 MAP kinase (mitogen-
activated protein kinase) inhibitors for the treatment of severe influenza and the
use of POLB 001 for the treatment of hypercytokinaemia. The Company continues to
seek broader patent protection for POLB 001 and p38 MAP kinase inhibitors in general
around the treatment and prevention of severe influenza and hypercytokinemia, and
has also filed patent applications, to expand its IP around POLB 001, to the use
of p38 MAP kinase inhibitors alongside cancer immunotherapies, enhancing the value
and attractiveness of POLB 001 to potential pharma partners.

> **Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented:**_“
> The grant received from the Japanese Patent Office highlights the progress we 
> are making in developing our patent portfolio. By strategically growing this exciting
> molecule’s intellectual property portfolio, we aim to enhance its overall value
> for our partners. POLB 001 stands poised to make a substantial impact on global
> health and has tremendous potential to address unmet medical needs worldwide across
> multiple disease areas.”_

Share on:
